It currently is very cheap for an entity to keep IPIX share
It currently is very cheap for an entity to keep IPIX share price down based on the current 11 cent or so share price. Take an example where a manipulator has a $27,500 daily bank-roll to buy up to 250,000 shares. For this example let’s say they are willing to take a half a cent loss on their transactions to keep the stock artificially low. A half cent loss currently represents 5% of the total share price and on 250,000 shares is only $1,250. That $1,250 daily loss is probably less expensive than what they are paying their paid bashers on a daily basis. The only reason they have to take this minor loss is that there are still some pesky longs that keep nibbling away at these depressed values. Both the paid bashers and the daily transaction hits are simply the price of poker to them.
Now let’s use the same example and we wake up some morning soon and the share price has spiked up to $3.00/share after a partnership announcement. There is an abundance of NEW buyers beyond the pesky longs that have been holding on for dear life. These new buyers drive REAL volume up to levels that we have previously never seen on IPIX as the entire biotech, pharmaceutical and Wall Street industries take notice and buy their tickets for a piece of a rising biotech star.
Back to our manipulator. That same $27,500 bank-roll would now only buy 9,166 shares vs the 250,000 shares currently. 9,166 shares will be a rounding error if legit volume raises to 500,000 to 1M shares daily. To control that same 5% of overall share price at $3 as the example above the manipulator would now have to take a daily hit of 15 cents vs a half a cent per share. A 15 cent loss on the same 250,000 shares would now be $37,500 loss per day vs only $1,250 currently. The cost of poker has just significantly gone up for the manipulator. The manipulator knows that $3/share is just the start as many of the new investors are just as pesky as the current longs and are looking for $10-$20/share exit strategies as Brilacidin and Kevetrin advance to market.
At some point the law of supply and demand wins. It always does.
11
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Merging Forces in Retail In the latest retail reshuffle, Spencer Spirit Holdings has wrapped up its acquisition of Hot Topic, Inc., alongside its eclectic sub-brands: BoxLunch and Her Universe. This move doubles down on Spencer Spirit's ambitions to tighten its grip on the mall-based specialty retail game. If you're an investor looking for a shake-up that could redefine...
Continue Reading
COFE Tech's Pre-IPO Raise: Scoring Big Dollars Today I'm reading this deal 'bout COFE Tech, and let me tell ya, there's more to chew over than a bowl of oatmeal. They just wrapped up a pre-IPO round at a hefty $178 million valuation. This wasn't just any ol' investment — we're talking about Wa'ed Ventures, the venture arm of Aramco, along with some heavy-hitter partners...
Continue Reading
Ace Hardware Signals Expansion Through 100th Store Anyone eying the hardware retail landscape knows that Ace Hardware is not just coasting through another predictable quarter. No, this coop, fondly dubbed the helpful hardware folks, has just cranked open the doors on its 100th new store of 2026. Yep, they're charging full-throttle on their expansion strategy, determined...
Continue Reading
A Looming Need for Home-based Care Take a long, deep breath and visualize this: by 2035, America's gonna need roughly 850,000 more home care workers. That's a head-spinning figure, and if you haven't been keeping up with the projections, let me fill you in on something the Bureau of Labor Statistics threw our way. They're saying home health and personal care aides will...
Continue Reading
ePlus Breaks Ground with Everpure There's a new chapter unfolding in the tech sector, and ePlus has carved its name on the marquee. Achieving the exclusive Ambassador Partner Status with Everpure, ePlus becomes the first in North America to hit this high note. In the crowded room of tech partnerships, this isn't just a pat on the back—it's a gold star that screams...
Continue Reading
Conference Spotlight: Endoscopic Brow Lift Plastic surgeons from across the globe are gathering in Crete, Greece, for a conference that promises to shake up the aesthetic world. Among the big names is Dr. John M. Anastasatos, who'll be lifting more than just eyebrows with his presentation on the endoscopic brow lift. This isn't just another facelift spiel—no sir—this...
Continue Reading
A Storm Brews Over Power Solutions International Look, if you're holding Power Solutions International (NASDAQ:PSIX) in your portfolio, it's time to perk up. The air's thick with talk that Kuehn Law, the firm with a head for shareholder litigation, is on their case. They're poking around, seeing if some executives got a little too creative with the truth. Word on the...
Continue Reading
Changing the Game in Rare Earths When Lindian Resources announces a partnership, it's not just window dressing. This time, they've linked arms with Carester SAS for a hefty venture into oxide separation. The scope? An 8,000-tonne REO facility in Kazakhstan, a place already stamped as a geological treasure chest. We're staring at what could potentially be a new dawn for...
Continue Reading
RMI and Moore Team Up for Strategic Evolution Let me tell ya, RMI Direct Marketing deciding to join forces with Moore’s AudienceFirst Media is a decision that’ll ripple through the data-driven waters for quite some time. They ain’t merging, mind you, but they’re definitely tying their ships together with a shared compass set on list management and brokerage...
Continue Reading
Here's a story you might not have expected—potassium fluoride is finding its spotlight! With the market projected to tick upwards from USD 0.43 billion in 2026 to USD 0.51 billion by 2032, there's more here than meets the eye. A steady CAGR of 2.9% might not scream excitement, but steady growth often does the trick in chemicals. Why the Buzz Around Potassium Fluoride?...
Continue Reading
Top 5 Most Recently Viewed Articles
Skywork Launches Mureka V7: A New Era in Music Production Skywork has officially unveiled its latest model, the Mureka V7, along with an innovative tech addition, the Mureka TTS V1. These groundbreaking models promise to reshape experiences for music creators and enthusiasts alike. Mureka V7: Crafting Exceptional Melodies The Mureka V7 is not just another update; it’s a...
Continue Reading
BOK Financial Earnings Report Insights BOK Financial (NASDAQ: BOKF) is gearing up to release its latest quarterly earnings report soon, and investors are eager to gain insight into the company’s financial health. Anticipation is building, with analysts projecting an earnings per share (EPS) of $1.98. This forthcoming report holds significant interest for those invested...
Continue Reading
Major Insider Purchase Lights a Fire Well, folks, let’s talk about Ashley McEvoy, the President and CEO over at Insulet (NASDAQ:PODD). She just dropped a cool $1.03 million on 4,300 shares of her own company. That’s no chump change—this ain't a casual lunch treat. This insider buy, filed with the SEC on February 23, shines a bright spotlight on her confidence in the...
Continue Reading
ClassOne Technology Partners with Applied Optoelectronics ClassOne Technology, an innovative provider of electroplating and processing tools for microelectronics manufacturing, is set to enhance Applied Optoelectronics Inc.'s (NASDAQ: AAOI) capabilities. The partnership revolves around the Solstice S8 system, specifically designed to meet the swelling demands of...
Continue Reading
Stock Performance of Ascendis Pharma Recently, Ascendis Pharma (NASDAQ: ASND) saw a decline in its stock price by 1%. This drop followed the company’s latest revenue forecast for Skytrofa, its treatment designed for growth hormone deficiency. The announcement came during the influential 43rd Annual JPMorgan Healthcare Conference, where CEO Jan Mikkelsen laid out the...
Continue Reading
